CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma.

Inclusion Criteria: * Classic Hodgkin lymphoma: * Relapsed patients after autologous hematopoietic stem cell transplantation who have already received Brentuximab-Vedotin and anti-PDL1 antibodies, OR * Primarily refractory patients who do not reach CR after rescue, including Brentuximab-Vedotin and anti-PDL1 antibodies. * Anaplastic large T-cell lymphoma (ALK+/ALK-) and peripheral T-cell lymphoma (NOS/Angioimmunoblastic): * \>90% of tumor cells expressing CD30 determined by immunohistochemistry, AND * Relapsed patients after autologous hematopoietic stem cell transplantation, OR * Primarily refractory patients (after first line, including anthracycline) who do not achieve CR after rescue. * All patients must sign an informed consent before starting any procedure. * All patients must have measurable disease (detected by PET-CT) at the time of inclusion. * Performance status: ECOG 0-1 * FEV1\> 39%; DLCO and FVC\> 39% of NV. * No significant ventricular dysfunction: EF \>45%. * Total bilirubin and transaminases \<3 times the maximum normal value, unless attributable to lymphoma. * Creatinine \<2 times the normal maximum value and clearance\> 40 mL/min. Exclusion Criteria: * Performance status: ECOG 2-4 * Prior allogeneic haematopoietic stem cell transplant. * Active hepatitis B, C or HIV infection * Active bacterial, fungal, or viral infection. * Evidence of CNS involvement by lymphoma.